What the FDA labels say about taking them together

Eculizumab and ravulizumab

Eculizumab's FDA label of July 8, 2026 names ravulizumab in its boxed warning section, and ravulizumab's label names eculizumab too. The eculizumab label: “ULTOMIRIS and SOLIRIS REMS SOLIRIS is available only through a restricted program under a REMS called ULTOMIRIS and SOLIRIS REMS, because of the risk of serious meningococcal infections.”

Check it at the source: the eculizumab FDA label on DailyMed (effective July 8, 2026, Alexion Pharmaceuticals Inc.); the ravulizumab FDA label on DailyMed (effective October 9, 2025).

What does the eculizumab label say about ravulizumab?

Eculizumab label, boxed warning
Because of the risk of serious meningococcal infections, SOLIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ULTOMIRIS and SOLIRIS REMS [see Warnings and Precautions (5.2) ].

Eculizumab label, warnings and precautions
ULTOMIRIS and SOLIRIS REMS SOLIRIS is available only through a restricted program under a REMS called ULTOMIRIS and SOLIRIS REMS, because of the risk of serious meningococcal infections [see Warnings and Precautions (5.1) ].

Source: FDA drug label (SOLIRIS), Alexion Pharmaceuticals Inc., effective July 8, 2026 (SPL set ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722), via openFDA; the full label on DailyMed

What does the ravulizumab label say about eculizumab?

Ravulizumab label, boxed warning
Because of the risk of serious meningococcal infections, ULTOMIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ULTOMIRIS and SOLIRIS REMS [see Warnings and Precautions (5.2) ].

Ravulizumab label, warnings and precautions
ULTOMIRIS and SOLIRIS REMS ULTOMIRIS is available only through a restricted program under a REMS called ULTOMIRIS and SOLIRIS REMS, because of the risk of serious meningococcal infections [see Warnings and Precautions (5.1) ].

Source: FDA drug label (Ultomiris), Alexion Pharmaceuticals Inc., effective October 9, 2025 (SPL set a9a590d9-0217-43c7-908d-e62a71279791), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Eculizumab generic labelers

0Ravulizumab generic labelers

	Eculizumab	Ravulizumab
Labeled for	n/a	n/a
Boxed warning	Yes	Yes
Pharmacy cost (NADAC)	n/a	n/a
Shortage now	No current entry	No current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?

Eculizumab: the full record
Ravulizumab: the full record
Check more medicines together: up to five at once